After two women with similar genetic mutations were found to have astoundingly low cholesterol, drug companies began racing to release a super-drug that mimics that cholesterol-destroying mutation. New York Times science writer Gina Kolata and the director of the National Heart, Lung, and Blood Institute, Dr. Gary Gibbons, discuss these findings, and whether a super-drug could make high cholesterol a thing of the past.
Genetic Mutation Holds Promise for Cholesterol-Busting Drug
(Getty Images)
Guests:
Gina Kolata, science reporter for the New York Times
Dr. Gary Gibbons, director of the National Heart, Lung, and Blood Institute at the National Institutes of Health
Sponsored